atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update Post published:August 16, 2021 Post category:Press Release
Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results Post published:August 16, 2021 Post category:Press Release
Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs Post published:August 16, 2021 Post category:Press Release
Cybin Announces Additional Adelia Milestone Achievements Post published:August 12, 2021 Post category:Press Release
Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use Post published:August 12, 2021 Post category:Press Release
Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption Post published:August 12, 2021 Post category:Press Release
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline Post published:August 12, 2021 Post category:Press Release
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions Post published:August 12, 2021 Post category:Press Release
Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th Post published:August 12, 2021 Post category:Press Release
Wesana Health Commences Functional Animal Study for Treatment of Traumatic Brain Injury Post published:August 11, 2021 Post category:Press Release